$ALUR News

Saudi Public Investment Fund Sells Entire Stake in Allurion Technologies, Exits Position of 1,148,436 Shares

Allurion Treats First Commercial Patients in the United States, Marking Major Milestone

Allurion Advances Plan to Regain Listing Compliance

Allurion Begins Training and On‑Boarding of U.S. Accounts, Marking Major Milestone in Expansion Strategy

Allurion Technologies shares are trading lower after the company announced its plan to appeal NYSE's delisting proceedings against the company after failing to regain listing compliance.

Allurion Intends to Appeal NYSE Notice of Delisting, Execute Plan to Regain Compliance, and Expects to Continue Trading on NYSE

Allurion Technologies Plans To Appeal NYSE's Delisting Decision

What's Going On With Allurion Stock On Wednesday?

Chardan Capital Upgrades Allurion Technologies (ALUR)

Allurion Announces Exercise of Warrants for $3.0 Million in Gross Proceeds

Allurion Technologies shares are trading lower after the company announced the pricing of a $3 million warrant exercise at $1.15

Allurion Technologies Announces $3M Warrant Exercise At $1.15 Per Share

Chardan Capital Upgrades Allurion Technologies to Buy, Raises Price Target to $3

Allurion Receives U.S. FDA Approval

Allurion Technologies shares are trading higher after the company announced FDA approval for its gastric balloon system application.

Allurion Technologies Announces FDA Approves Allurion Gastric Balloon System Application

Allurion Announces Partnership to Offer Combination Therapy with Mounjaro® (tirzepatide) at Discounted Prices

Allurion Partnership To Offer Combination Therapy with Mounjaro At Discounted Prices

Allurion Technologies shares are trading higher after the company issued Q4 preliminary revenue guidance above estimates.

Allurion Announces Preliminary Fourth Quarter and Full-Year 2025 Results